Geode Capital Management LLC Purchases 294,617 Shares of Eton Pharmaceuticals, Inc. $ETON

Geode Capital Management LLC raised its position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 98.8% during the second quarter, Holdings Channel.com reports. The institutional investor owned 592,865 shares of the company’s stock after purchasing an additional 294,617 shares during the quarter. Geode Capital Management LLC’s holdings in Eton Pharmaceuticals were worth $8,450,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. AlphaQuest LLC bought a new position in shares of Eton Pharmaceuticals in the first quarter valued at approximately $53,000. Quantbot Technologies LP bought a new position in Eton Pharmaceuticals in the 1st quarter valued at $101,000. Wellington Management Group LLP acquired a new position in Eton Pharmaceuticals in the first quarter worth $328,000. Envestnet Asset Management Inc. boosted its stake in Eton Pharmaceuticals by 33.1% in the second quarter. Envestnet Asset Management Inc. now owns 23,050 shares of the company’s stock worth $328,000 after purchasing an additional 5,734 shares in the last quarter. Finally, PDT Partners LLC bought a new stake in shares of Eton Pharmaceuticals during the first quarter worth $334,000. Institutional investors own 27.86% of the company’s stock.

Analyst Ratings Changes

ETON has been the subject of a number of research analyst reports. Wall Street Zen raised Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, September 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Zacks Research cut shares of Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, November 13th. Three investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, Eton Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $29.67.

Eton Pharmaceuticals Trading Up 1.9%

ETON opened at $16.81 on Friday. The firm’s fifty day moving average is $18.23 and its two-hundred day moving average is $17.02. The firm has a market cap of $450.84 million, a PE ratio of -67.24 and a beta of 1.17. Eton Pharmaceuticals, Inc. has a twelve month low of $11.09 and a twelve month high of $23.00. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.25 and a current ratio of 1.63.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.20). The firm had revenue of $22.46 million during the quarter, compared to the consensus estimate of $20.47 million. Eton Pharmaceuticals had a negative net margin of 9.50% and a negative return on equity of 11.32%. Equities research analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current year.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.